Thursday, July 07, 2022 10:17:44 AM
Director/Senior Director, Global Pharmacovigilance
About the job
Summary of Position
Anavex Life Sciences Corp. is seeking a talented and highly motivated pharmacovigilance director/Sr. director to join our team. This position will have full responsibility for Drug Safety activities for assigned projects in clinical trials. This includes meeting internal and external sponsor requirements according to time, quality, scope, and budget parameters. The Pharmacovigilance director is the primary point of contact for Drug Safety on a project, for internal project team members, sponsors, investigators, and vendors. This role encompasses the coordination of a variety of Drug Safety activities such as the collection, detection, assessment, monitoring, and prevention of adverse events and effects with pharmaceutical products. The role requires a careful and precision-based mindset that looks ahead to predict and prevent safety problems before they occur in clinical trials and other pharmaceutical related projects.
Key Responsibilities
Act as the both the Global Pharmacovigilance director and key contact point for regulatory authorities on PV related issues
Build GPV leadership team to set up, select and onboard PV vendor/CRO and maintain an efficient PV system in compliance with national regulations
Track and report any regulatory authorities or business changes impacting pharmacovigilance and support the development and implementation of procedures
Serve as a key liaison between the Global Clinical Team and third-party vendors for the management of adverse event reports from company sponsored clinical studies.
Lead safety operations activities related to clinical trials, and closely interact with Research & Development stakeholders to ensure an appropriate safety monitoring of clinical trials subjects
Work in collaboration Global Clinical Operations to maintain the pharmacovigilance section of the Trial Master File/Sponsor Oversight Files to ensure sections related to clinical safety are accurate and up to date
Lead the creation and review of important PV documents such as DSUR, IB updates, Annual Safety reports
Drive and support activities related to company sponsored clinical trials to provide required pharmacovigilance contributions such the drafting of Safety Management Plan (SMP), and the review of protocols, inform consent forms (ICF), and other clinical documents as required
Lead Global Pharmacovigilance and work with Global Clinical Operations, Regulatory Affairs, and Clinical Research Organization to ensure a timely submission of pharmacovigilance reports (SUSARs, DSURs, REMS, and other safety communications, etc.) to regulatory authorities and IRBs/ECs
Represent pharmacovigilance at a variety of business meetings, including project team meeting, vendor evaluation meetings, vendor oversight meetings, and other ad hoc meetings as assigned. Support audit/regulatory inspections and work closely with GPV leadership in the implementation and management of CAPAs following the audits/inspections
Ensure direct reports training records are up to date, including SOPs and yearly Pharmacovigilance refresher training
Responsible for receipt, timely forwarding, collection, and follow-up of individual case safety reports (ICSRs) as well as monthly reconciliation activities including maintenance of local site file/trackers when required
Provide the needed support in the scheduling compilation and timely submissions of Periodic Adverse Drug Experience Reports (PADERS) and other aggregate safety reports to the FDA and EMA
Have oversight of other programs like non-interventional studies, safety studies and local registries and websites
Provide relevant information as needed for the compilation of the Pharmacovigilance Master File (PSMF)
Support the development and maintenance of Safety Data Exchange Agreements
Represent the US site in discussion of safety operation issues at global functional team meetings
Help in generating and tracking KPIs in monitoring site/regional compliance.
Ensure appropriate filing and archiving of Pharmacovigilance related documents is performed
Requirements
Registered Nurse (BSN, MSN), relevant Master with previous PV experience, Pharmacists (RPh or PharmD), or Medical Doctor (MD, DO)
5 to 10 years’ related experience in a biotechnology or pharmaceutical company or CRO environment
5 to 8 years’ experience in Pharmacovigilance and quality assurance - tactical, operational and strategic capacities is preferred
Strong experience in the conduct and management of clinical trials, especially phase II and phase III clinical trials (CNS experience preferred but not mandatory)
Personnel management and supervisory experience is required
Excellent verbal and written communication skills, proof reading and organization skills
Comprehensive and working knowledge of Microsoft Outlook, Microsoft WORD, Excel and PowerPoint. Electronic document management experience a plus
Ability to handle sensitive material in a confidential manner
Strong attention to detail and follow-up skills
Maintain a high level of diplomacy, discretion, maturity and sound judgement
Must be flexible and willing to take on significant administrative responsibilities
Must take initiative and have ability to work independently and as a team member, and helping wherever needed
Must be able to create contingency plans to deal with possible challenges and roadblocks
Remote position; intermittently required to work on-site in New York City; occasional travel.
Recent AVXL News
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM